^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA inhibitor

    Related drugs:
    8d
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=224, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    cyclophosphamide
    11d
    ISG-MCS: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (clinicaltrials.gov)
    P2, N=16, Recruiting, Italian Sarcoma Group | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NCOA2 (Nuclear Receptor Coactivator 2)
    |
    Yondelis (trabectedin)
    13d
    Schlafen 11 as a prognostic and potentially predictive biomarker in soft tissue sarcoma: evidence from a real-world cohort. (PubMed, Front Oncol)
    Sub-cohorts included patients receiving neoadjuvant therapy (n = 33), primary resection (n = 193), palliative first-line chemotherapy (n = 26), or a palliative salvage therapy with trabectedin (n = 22)...SLFN11 is a prognostic and potentially predictive biomarker in STS in the context of chemotherapy. Our results support a prospective validation, standardization of SLFN11 assessment, and consecutive clinical implementation.
    Journal • Real-world evidence
    |
    SLFN11 (Schlafen Family Member 11)
    |
    Yondelis (trabectedin)
    13d
    ISG-ARTICLE: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Italian Sarcoma Group | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    gemcitabine • Yondelis (trabectedin)
    15d
    The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (clinicaltrials.gov)
    P=N/A, N=114, Not yet recruiting, Guy's and St Thomas' NHS Foundation Trust | Trial completion date: Jun 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027
    Trial completion date • Trial primary completion date
    17d
    FORMaT-EVOLVE: Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, The University of Queensland
    New P2 trial
    22d
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ropidoxuridine (IPdR)
    27d
    SYNERGIAS: Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (clinicaltrials.gov)
    P2, N=85, Recruiting, Grupo Espanol de Investigacion en Sarcomas | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yondelis (trabectedin) • dexamethasone injection • ondansetron
    28d
    Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir (clinicaltrials.gov)
    P4, N=40, Recruiting, Riphah International University | Active, not recruiting --> Recruiting
    Enrollment open
    28d
    Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (clinicaltrials.gov)
    P2, N=48, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • Yondelis (trabectedin)
    1m
    PRoHerpARD: Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases (clinicaltrials.gov)
    P4, N=62, Not yet recruiting, University of Sao Paulo General Hospital | Trial primary completion date: Dec 2027 --> Apr 2027
    Trial primary completion date
    1m
    Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir (clinicaltrials.gov)
    P4, N=40, Active, not recruiting, Riphah International University
    New P4 trial